Skip to content
In English |
En español
National Cancer Institute
at the National Institutes of Health
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Popular Resources
Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-5 of 5 for your search:
Drug:
tetanus toxoid helper peptide
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Randomized Study of Adjuvant Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides in Combination With Either Multi-Epitope Melanoma Helper Peptides or Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 With Versus Without Cyclophosphamide in Patients With Resected Stage IIB-IV Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UVACC-HIC-11491
, Mel 44, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, NCT00118274
2.
Phase II Study of Vaccine Therapy Comprising Synthetic Ovarian Cancer-Associated Peptides Administered With a Synthetic Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 Before or After Paclitaxel and Carboplatin in Patients With Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Undergoing Optimal Cytoreductive Surgery
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UVACC-OVA-2
, OVA-2, UVACC-HIC-10134, UVACC-PRC-236-02, NCT00373217
3.
Phase I Study of Adjuvant Vaccine Comprising Ovarian Cancer Synthetic Peptides, Tetanus Toxoid Helper Peptide, and Sargramostim (GM-CSF) Emulsified in Montanide ISA-51 in Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Cancer
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UVACC-OVA3
, UVACC-33204, UVACC-HIC-11276, NCT00091273
4.
Phase I Randomized Study of Adjuvant Transdermal Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides, Tetanus Toxoid Helper Peptide, and Sargramostim (GM-CSF) in Combination With Either Montanide ISA-51 or Dimethyl Sulfoxide With or Without Imiquimod in Patients With Resected Stage II-IV Melanoma
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
12 and over
Sponsor:
NCI
Protocol IDs:
UVACC-MEL-45
, UVACC-HIC-11490, UVACC-34204, NCT00118313
5.
Vaccine Therapy in Treating Patients With Advanced Melanoma
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI, Other
Protocol IDs:
13498
, R01CA057653, P30CA044579, UVACC-MEL-48, UVACC-IRB-13498, UVACC-PRC-450-07, Mel 48, NCT00705640
Select All on Page
Help with Results
We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat
NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map
Other Versions of this Site:
Mobile
|
Español
Follow Us:
Twitter
YouTube
Facebook
RSS
NIH…Turning Discovery Into Health
®
Mobile | Español
Mobile | Español
